Piramal Enterprises Limited

July 08, 2022

Ratings

Facilities/Instruments	Amount (₹ crore)	Rating[1]	Rating Action
Market-linked debentures	1,000.00	CARE PP-MLD AA; Stable (Principal Protected-Market-linked Debentures Double A; Outlook: Stable)	Assigned
Market-linked debentures	2,000.00	CARE PP-MLD AA; Stable (Principal Protected-Market-linked Debentures Double A; Outlook: Stable)	Reaffirmed and removed from Credit watch with Developing Implications; Stable outlook assigned
Non-convertible debentures	3,800.00	CARE AA; Stable (Double A; Outlook: Stable)	Reaffirmed and removed from Credit watch with Developing Implications; Stable outlook assigned
Total long-term instruments	**6,800.00 (₹ Six thousand eight hundred crore only)**		
Commercial paper	6,000.00	CARE A1+ (A One Plus)	Reaffirmed
Inter-corporate deposit	250.00	CARE A1+ (A One Plus)	Reaffirmed
Short-term non-convertible debentures	-	-	Withdrawn
Total short-term instruments	**6,250.00 (₹ Six thousand two hundred fifty crore only)**		
Long-term bank facilities	1,000.00	CARE AA; Stable (Double A; Outlook: Stable)	Reaffirmed and removed from Credit watch with Developing Implications; Stable outlook assigned
Short-term bank facilities	1,000.00	CARE A1+ (A One Plus)	Reaffirmed
Total bank facilities	**2,000.00 (₹ Two thousand crore Only)**		

Details of instruments/facilities in Annexure-1

Detailed rationale and key rating drivers

CARE Ratings Limited (CARE Ratings) has taken a consolidated view of financial services business (PEL FS) of Piramal Group which includes 'Piramal Enterprise Limited (PEL)' and its two 100% owned subsidiaries 'PHL Fininvest Private Limited (PFPL)' and Piramal Capital and Housing Ltd. (PCHFL; erstwhile Dewan Housing Finance Ltd [DHFL])'.

Earlier CARE has placed the ratings on 'credit watch with developing implications' on account of PCHFL being declared as the successful resolution applicant in relation to the Corporate Insolvency Resolution Process of DHFL under the Insolvency & Bankruptcy Code, 2016 and the subsequent announcement of the Scheme of Arrangement to demerge the pharmaceuticals business of PEL and merge PFPL into PEL subject to approval from majority of the shareholders, creditors of the companies, Securities and Exchange Board of India (SEBI), stock exchanges, National Company Law Tribunal (NCLT) and other regulatory authorities as applicable.

PCHFL acquired DHFL and got reverse merged into DHFL on September 30, 2021 and was subsequently renamed 'Piramal Capital and Housing Finance Limited' which continues to remain a wholly-owned subsidiary of PEL.

As per the scheme of arrangement being undertaken within the Piramal Group, the pharmaceutical (pharma) business would demerge from PEL and consolidate it under Piramal Pharma Ltd (PPL) and PPL would be separately listed in stock exchanges. Furthermore, PEL is envisaged to become a non-banking financial company (NBFC) with PFPL getting merged with it.

The restructuring of the business is expected to be completed by Q3FY23, subject to the shareholders, creditors and regulatory approvals, post which the financial services would be conducted through PEL, which will become an NBFC, whereas PCHFL

[1]Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

would continue to be its wholly-owned housing finance company (HFC). PEL is expected to retain all the non-pharma-related assets, including the shareholding in the Shriram group.

The financial services contributed around 52% (P.Y.: 55%) while the pharma segment contributed around 48% of consolidated revenue of PEL for FY22 (refers to the period April 1 to March 31) (FY21: 45%). Although, the demerger of the pharma business would impact the total revenue of PEL going ahead; the revenue and the business risk profile of PEL FS would not change on account of the demerger.
PEL FS business is sufficiently capitalised as the majority of equity (₹30,104 crore out of ₹35,489 crore as on March 31, 2022) of PEL consolidated will remain in PEL after demerger (Out of ₹30,104 crore equity expected to continue in PEL post demerger, ₹10,760 crore still remains unallocated and is available for future allocation in the financial services business). The demerger is not expected to have a material impact on the credit profile of PEL FS as it is sufficiently capitalised and has diversified loan book post DHFL takeover.
Based on the above factors, CARE Ratings has reaffirmed the ratings assigned to the debt instruments and bank loan facilities of PEL and removed the credit watch on the long-term ratings and has assigned stable outlook.

The ratings continue to factor in the long track record of the promoter group in financial services business, financial flexibility of promoter group and moderate leverage of PEL FS business supported by strong capitalisation levels. The rating also takes note the group’s plan to bring in more granularity to the loan book by focusing on the retail segment and the significant increase in retail proportion due to acquisition of DHFL wherein share of retail in total loan book increased from 11% of assets under management (AUM) as on March 31, 2021 to 33% of AUM as on March 31, 2022.
The rating strengths are partially constrained by PEL FS’s moderation in asset quality as well as significant exposure to and concentration in the real estate loan portfolio, which although the group has been taking measures to reduce, remains sizeable and the ability of PEL FS to raise funds from diverse sources at competitive rates remains a key rating monitorable.
CARE has withdrawn the rating assigned to short term NCD of ₹450 crore at the request of the company as these NCDs have been never been issued.

Rating sensitivities
Positive factors - Factors that could lead to positive rating action/upgrade:
- Substantial reduction in exposure to the real estate segment in overall loan book and single group exposure of consolidated tangible net worth on a sustained basis
- Significant improvement in asset quality

Negative factors- Factors that could lead to negative rating action/downgrade:
- Increase in the proportion of real estate loan book of PEL FS on a sustained basis
- Mismatch in asset liability maturities and challenges in raising long-term funding
- Deterioration in asset quality with net non-performing asset (Net NPA)/ Net worth (excluding pharma) of over 10% at PEL level
- Increase in the overall gearing beyond 3.5x for PEL level (excluding pharma)

Detailed description of the key rating drivers
Key rating strengths
Strong and resourceful promoters along with experienced management team:
PEL is the flagship company of the Piramal group headed by the Chairman, Mr Ajay Piramal. The group has presence in diversified businesses like financial services, pharma (CDMO, Critical Care, OTC) and real estate development and consulting (through a separate company). The Board of Directors has eminent persons from the industry providing their experience and governance to the group. The Board is supported by experienced senior management team heading various verticals with adequate and relevant experience in their respective fields.
The group has experience of lending in the real estate industry for over a decade and forayed into mortgage lending around five years back.
The focus of the group has now shifted towards building the retail portfolio in the financial services segment and the group has appointed Mr. Jairam Sridharan as the Managing Director (MD of PCHFL) to head and scale up its retail finance business in the medium term. Mr. Sridharan has over two decades of retail domain experience and specialises in setting up and scaling new businesses. The group is in the process of building team, systems and process to undertake retail book expansion. Further, acquisition of DHFL has helped the group to diversify its retail book and will help launch various retail products.

Demonstrated financial flexibility through fund raising leading to comfortable capitalisation and gearing levels:
PEL has demonstrated strong fund-raising capability in the recent past and has raised equity capital and has been providing growth capital to its subsidiaries including pharma and financial services business. During FY20 and FY21, PEL raised nearly ₹18,173 crore of capital by way of sale of 10% stake in Shriram Transport Finance Company Ltd (₹2,300 crore in June 2019), Rights issue (₹3,650 crore including promoter investment of ₹1,600 crore in January 2020), preferential allotment to Caisse de dépôt et placement du Québec (CDPQ) (₹1,750 crore in December 2019), sale of its DRG business (₹6,750 crore in February 2020) and stake dilution by 20% in PPL to the Carlyle group (₹3,523 crore in October 2020). These funds were used to deleverage the balance sheet and provide capital for its financial services business. Furthermore, to add comfort to the capital requirement in PEL FS, PEL has financial flexibility in terms of its holdings in the Shriram group (20% in Shriram Capital and 10% in Shriram City Union Finance).

Of the total consolidated equity of ₹35,489 crore as on March 31, 2022, equity of ₹5,385 crore pertains to the pharma division which is expected to be transferred due to demerger and ₹30,104 crore (PEL FS: ₹17,006 crore + Alternatives: ₹1,381 crore + Life Insurance: ₹1,381 crore and Unallocated: ₹10,760 crore) will remain in the PEL post the demerger. PEL had an overall gearing of 1.64x (considering total equity excluding marked towards pharma) and 2.9x for PEL FS as on March 31, 2022. Any material deviation of the equity towards non-FS business, thereby increasing the leverage of the FS business would be a key rating sensitivity.
PEL FS had capital adequacy ratio (CAR) of 21.00% (P.Y.: 36.00%). PCHFL (standalone) reported CAR of 22.01% (P.Y.: 32.30%) with Tier I CAR of 21.11% (P.Y.: 32.03%) as on March 31, 2022 while PFPL (standalone) reported CAR of 50.42% (P.Y.: 39.10%) with Tier I CAR of 49.17% (P.Y.: 38.80%) as on March 31, 2022.

Moderation in profitability with higher provisioning:
PEL FS's Net Interest income was lower by 13% at ₹2,406 crore during FY22 on account of interest reversals on some assets that were moved from Stage-1 to Stage-2 and due to negative carry for maintaining excess liquidity on the balance sheet. Fee income increased as off-balance sheet securitized assets (₹18,747 crore as on March 31, 2022) acquired with DHFL generated fee income around 1.6%. Furthermore, operating expenses increased substantially during FY22 as PEL FS took over DHFL increasing the employee count and expenses for reopening branches causing the Pre-Provision Operating Profit (PPOP) to be lower by 25% in FY22 at ₹1,694 crore as compared with the previous year. Provisions were high during FY22 mainly on account of some large assets being classified as Stage-2 in Q4FY22 requiring incremental provisioning. As a result, profit after tax (PAT) was lower by 55% at ₹743 crore for FY22 as compared with ₹1,668 crore for the previous year. Return on total assets (ROTA) was 1.3% for FY22 (FY21: 3.3%).

Key rating weaknesses
Concentration risk in PEL FS:
The lending portfolio of PEL FS has predominantly been wholesale with high concentration on the real estate segment. The group is focused on growing the retail book and the acquisition of DHFL has helped reduce the wholesale proportion from 89% of AUM as on March 31, 2021 to 67% as on March 31, 2022, although the same continues to be remain high and is expected to reduce in the medium term as the company scales up its retail business. Although, the real estate exposure has also come down from 78% of the AUM as on March 31, 2021 to 45% of the AUM as on March 31, 2022, the sector risk still persists.
While the management is trying to reduce the wholesale exposure especially in real estate and client concentrations on an absolute basis, the progress has been slower than expected. The wholesale loan book is gradually reducing. Majority of retail portfolio comprises of housing loans acquired from DHFL and a small portion of its own book. PEL FS division has started to diversify its retail book by launching new products such as unsecured loans, small and medium enterprises (SME) credit, used vehicle financing, personal loans, etc. and have made partnerships with fintech firms to get business. The retail division is gaining traction from Q2FY22 with the acquisition of DHFL portfolio helped by improvement in retail disbursements. Top 10 group exposures constituted around 19% of AUM as on March 31, 2022 (March 31, 2021: 28%).

Moderate asset quality
The Gross NPA ratio of PEL FS reduced from 4.1% as on March 31, 2021 to 3.4% of overall AUM as on March 31, 2022, on account of addition of DHFL assets from September 30, 2021 onwards. DHFL's Stage-3 and Stage-2 assets as on merger date (amounting to face value of ₹9,488 crore), has been classified as Purchased or Originated Credit Impaired (POCI) at a fair value of ₹3,465 in PEL FS's book as on March 31, 2022, and these accounts will not get reclassified as Stage-1 / 2 / 3 assets in their lifecycle. PEL FS continues to keep sufficient provisions at 5.7% of AUM as on March 31, 2022, to insulate itself from any further asset quality shocks. Stage-2 assets constitute 6.25% of AUM while Restructured assets and Emergency Credit Line Guarantee Scheme (ECLGS) loans constitute around 3% and 1.6% of AUM respectively as on March 31, 2022. PEL FS has extended the date of commencement of commercial operations (DCCO) in respect of loans to commercial real estate projects of around 7% of the AUM as on March 31, 2022. While PEL FS has adequate provisioning, asset quality will remain key monitorable going forward.

Ability to raise funds at competitive rates:
Majority of borrowings of PEL FS are in the form of NCD instruments as on March 31, 2022 and the largest category of lenders are banks. The weighted average maturity profile of borrowings at PEL FS level is 3.7 years as on March 31, 2022. PEL FS has in the past refinanced its debt and lowered its average borrowing cost. PEL FS also continues to hold high quantum of liquidity of ₹8,825 crore as on March 31, 2022 which is around 18% of the total debt of PEL FS and scheduled collections from the loan portfolio and prepayments of housing portfolio acquired from DHFL provides additional comfort. The ability of PEL FS to raise long-term funds at competitive rates from varied sources to fund its incremental loan book as well as repay its debt is a key rating sensitivity.

Liquidity: Adequate
According to the Structural Liquidity Statement as on March 31, 2022, there were no negative cumulative mismatches as per the asset-liability management (ALM) of PEL FS in time buckets up to six months. PEL FS had cash and cash equivalents including unutilised bank lines of around ₹8,825 crore as on March 31, 2022 (March 31, 2021: ₹9,180 crore) as against repayments due of ₹10,207 crore over FY23. PEL also has access to the capital market and raise funds through CP. Furthermore, it also has minority stake in the Shriram group companies which acts as an additional buffer.

PFPL had a cash and bank equivalents including unutilised bank lines of around ₹432 crore as on March 31, 2022, as against repayments due of ₹1,440 crore during FY23. However, PFPL can borrow from PEL and PCHFL in the form of ICDs to repay the external debt.
PCHFL had a cash and bank equivalents including unutilised bank lines of around ₹6,830 crore as on March 31, 2022, as against repayments due of ₹6,671 crore during FY23.

Analytical approach:
CARE Ratings has taken a consolidated view of the credit profiles of PEL (excluding pharma business) and its subsidiaries – PCHFL and PFPL considering the ongoing restructuring of business within the Piramal group.

Applicable Criteria
Policy on default recognition
Consolidation
Financial ratios – Financial sector
Rating Outlook and Credit Watch
Short Term Instruments
Rating Methodology- Non-Banking Finance Companies
Policy on Withdrawal of Ratings

About the Company – Piramal Enterprises Ltd
Piramal Enterprises Limited (PEL) is the flagship holding company (listed) of the Ajay Piramal group of companies with presence in Pharmaceuticals (CRAMS, Critical Care, Over the Counter (OTC) through Piramal Pharma Limited (PPL) and financial services business (PEL FS), largely through wholly-owned subsidiaries PCHFL and PFPL.
Piramal pharma, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes: Pharma Solutions, an integrated contract development and manufacturing (CDMO) business; Critical Care, a complex hospital generics business and the Consumer Healthcare business, selling over-the-counter products in India. As per the restructuring being undertaken within the Piramal Group the pharmaceutical division would demerge from PEL and consolidate under Piramal Pharma Ltd (PPL) and PPL would be separately listed in stock exchanges. The Carlyle group which now holds 20% of PPL, with 80% being held by PEL, will continue to hold 20% of PPL and the shareholders of PEL will get the shares of PPL and PEL will no longer be a shareholder of PPL.
PEL FS in real estate provides housing finance and other financing solutions across the entire capital stack ranging from early stage private equity, structured debt, senior secured debt, construction finance and flexi lease rental discounting. The wholesale segment (other than real estate) has Corporate Finance Group (CFG) providing customised funding solutions to companies across sectors such as infrastructure, renewable energy, roads, industrials, auto components etc. while and Emerging Corporate Lending (ECL) focuses on lending towards SMEs. PEL FS has planned to diversify its retail book by including innovative tech-driven unsecured loans, SME credit, used vehicle financing, personal loans, etc. PEL FS also has several tie-ups with leading international partners like Bain Capital (for stressed asset), APG (mezzanine investment in Infra), Ivanhoe Cambridge (Residential real estate platform), CDPQ (Senior Debt in non-Real Estate, non-Infra sectors), CPPIB (InvIT platform of Renewables), etc.

PEL Consolidated

Brief Financials (₹ crore)	31-03-2021 (A)	31-03-2022 (A)
Total operating income	12,809	13,993
PBILDT	7,828	7,170
PAT	1,413	1,999
Overall gearing (times)	1.19	1.49
Interest coverage (times)	1.86	1.60

A: Audited

PEL FS
PEL FS refers to the financial services business of PEL. This includes the real estate lending, corporate and emerging corporate lending, MSME lending and retail lending businesses. PEL FS has been diversifying its retail book by including innovative tech-driven products. PEL FS had AUM of ₹65,185 crore as on March 31, 2022 (March 31, 2021: ₹48,891 crore).

PEL FS (Key financial indicators)

Brief Financials (₹ crore)	31-03-2021	31-03-2022
Total operating income	2,883	2,768
PAT	1,667	743
Net NPA (%)	2.1	1.6
ROTA (%)	3.3	1.3

*Based on AUM

About the Company – PHL Fininvest Pvt. Ltd. (PFPL)
PHL Fininvest Private Ltd., a wholly-owned subsidiary of Piramal Enterprises Limited (PEL), the flagship company of the Piramal group, is registered as a non-banking financial company with Reserve Bank of India (RBI) and engaged in financial services business. It provides funding opportunities within real estate and non-real estate sectors, such as infrastructure, hospitality, automotive, financial services, transport, renewable energy, entertainment, etc. The company was incorporated in June 1994 in the name of NPIL Fininvest Private Limited. Later, the name of the company was changed to PHL Fininvest Private Limited w.e.f. December 26, 2008. In June 2000, PHL Fininvest Private Limited received a certificate for commencing business of non-banking financial institution without accepting public deposit from RBI. The company had no material operations till FY18. During FY19, a part of the loan portfolio (largely corporate lending and real estate related loans) was transferred to PFPL from PEL and Piramal Capital and Housing Finance Limited (PCHFL). PFPL had a major part of its borrowings by way of inter-corporate deposits (ICDs) from PEL and PCHFL. PFPL had AUM of ₹10,349 crore as on March 31, 2022 (March 31, 2021: ₹12,406 crore).

PFPL Standalone

Brief Financials (₹ crore)	31-03-2021 (A)	31-03-2022 (A)
Total operating income	2,008	1,568
PAT	491	423
Total Assets	13,001	11,079
Net NPA (%)*	2.3	2.8
ROTA (%)	3.5	3.5

A: Audited
*Based on AUM

About the Company – Piramal Capital and Housing Finance Ltd. (PCHFL)
Erstwhile PCHFL (formerly Piramal Housing Finance Limited (PHFL) is a housing finance company, incorporated in February 2017 as wholly owned subsidiary of Piramal Finance Limited. With effect from March 31, 2018, Piramal Finance Limited and Piramal Capital Limited have amalgamated with Piramal Housing Finance Limited and subsequently, the name of the entity has changed to Piramal Capital & Housing Finance Limited. PCHFL has become a wholly-owned subsidiary of Piramal Enterprise Limited (PEL) and is the flagship entity of the group's financial services business. Pursuant to the resolution plan and take over by the Piramal group, PCHFL was reverse merged into DHFL with effect from September 30, 2021 as contemplated under scheme of arrangement provided under the resolution. DHFL was subsequently renamed as 'Piramal Capital & Housing Finance Limited' since November 2021. PCHFL had AUM of ₹51,808 crore as on March 31, 2022 (March 31, 2021: ₹32,353 crore).

PCHFL Standalone

Brief Financials (₹ crore)	31-03-2021 (A)	31-03-2022 (A)
Total operating income	5,088	6,187
PAT	1,034	526
Total Assets	42,357	69,466
Net NPA (%)*	1.9	1.1
ROTA (%)	2.50	0.94

A: Audited
*Based on AUM

Status of non-cooperation with previous CRA:
Not applicable

Any other information:
Not applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated for this company: Annexure 4

Annexure-1: Details of Instruments / Facilities

Name of the Instrument	ISIN	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (₹ crore)	Rating assigned along with Rating Outlook
Fund-based - LT-Term loan		Proposed	-	-	1,000.00	CARE AA; Stable
Fund-based - ST-Working capital limits		-	-	-	1,000.00	CARE A1+
Non-convertible debentures	INE140A07179	14-Jul-16	9.75%	14-Jul-26	35.00	CARE AA; Stable
Non-convertible debentures	INE140A07211	19-Jul-16	9.75%	17-Jul-26	5.00	CARE AA; Stable
Non-convertible debentures	INE140A07591	21-May-20	8.55%	19-May-23	500.00	CARE AA; Stable
Non-convertible debentures	INE140A07609	25-Jun-20	9.00%	26-Jun-23	2,590.00	CARE AA; Stable
Non-convertible debentures	INE140A07617	07-Jul-20	9.50%	07-Jul-23	76.00	CARE AA; Stable
Non-convertible debentures	INE140A07179	Proposed	-		594.00	CARE AA; Stable
Market-linked debentures	INE140A07641	12-Jul-21	8.15%	12-Jan-23	102.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07633	28-Jun-21	8.25%	28-Jun-23	365.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07633	5-Jul-21	8.25%	28-Jun-23	125.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07658	27-Sep-21	8.00%	27-Mar-24	400.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07682	24-May-22	8.00%	24-May-24	100.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07666	2-Mar-22	8.00%	2-Sep-24	125.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07666	28-Mar-22	8.00%	2-Sep-24	175.00	CARE PP-MLD AA; Stable
Market-linked debentures	INE140A07674	4-May-22	8.00%	4-Nov-24	100.00	CARE PP-MLD AA; Stable
Market-linked debentures	-	Proposed	-	-	1,508.00	CARE PP-MLD AA; Stable
Commercial paper	-	7-365 days	-	-	6,000.00	CARE A1+
Inter-corporate deposit	-	Upto 365 days	-	-	250.00	CARE A1+

Annexure-2: Rating history of last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021	Date(s) and Rating(s) assigned in 2019-2020
1	Debentures-Non Convertible Debentures	-	-	-				
2	Debentures-Non Convertible Debentures	LT	100.00	CARE AA; Stable	1)CARE AA (CWD) (06-Apr-22)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Dec-19) 2)CARE AA; Stable (06-May-19)
3	Commercial Paper-Commercial Paper (Standalone)	ST	5000.00	CARE A1+	1)CARE A1+ (06-Apr-22)	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20) 4)CARE A1+ (28-Apr-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021	Date(s) and Rating(s) assigned in 2019-2020
4	Fund-based - LT-Term Loan	LT	1000.00	CARE AA; Stable	1)CARE AA (CWD) (06-Apr-22)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Dec-19) 2)CARE AA; Stable (06-May-19)
5	Inter Corporate Deposit	ST	250.00	CARE A1+	1)CARE A1+ (06-Apr-22)	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)
6	Commercial Paper-Commercial Paper (Standalone)	ST	1000.00	CARE A1+	1)CARE A1+ (06-Apr-22)	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20) 4)CARE A1+ (28-Apr-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)
7	Non-fund-based - ST-BG/LC	ST	-	-	-	-	1)Withdrawn (30-Dec-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)
8	Fund-based - ST-Working Capital Limits	ST	1000.00	CARE A1+	1)CARE A1+ (06-Apr-22)	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20)	1)CARE A1+ (30-Dec-19) 2)CARE A1+ (06-May-19)
9	Debentures-Non Convertible Debentures	ST	-	-	1)CARE A1+ (06-Apr-22)	1)CARE A1+ (11-Oct-21)	1)CARE A1+ (31-Mar-21) 2)CARE A1+ (28-Jan-21) 3)CARE A1+ (30-Dec-20)	1)CARE A1+ (30-Dec-19)
10	Debentures-Non Convertible Debentures	LT	450.00	CARE AA; Stable	1)CARE AA (CWD) (06-Apr-22)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA	1)CARE AA; Stable (30-Dec-19)

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021	Date(s) and Rating(s) assigned in 2019-2020
							(CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	
11	Debentures-Non Convertible Debentures	LT	250.00	CARE AA; Stable	1)CARE AA (CWD) (06-Apr-22)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20)	1)CARE AA; Stable (30-Mar-20)
12	Debentures-Non Convertible Debentures	LT	3000.00	CARE AA; Stable	1)CARE AA (CWD) (06-Apr-22)	1)CARE AA (CWD) (11-Oct-21)	1)CARE AA (CWD) (31-Mar-21) 2)CARE AA (CWD) (28-Jan-21) 3)CARE AA; Stable (30-Dec-20) 4)CARE AA; Stable (24-Apr-20)	-
13	Debentures-Market Linked Debentures	LT	1000.00	CARE PP-MLD AA; Stable	1)CARE PP-MLD AA (CWD) (06-Apr-22)	1)CARE PP-MLD AA (CWD) (11-Oct-21) 2)CARE PP-MLD AA (CWD) (17-Jun-21)	-	-
14	Debentures-Market Linked Debentures	LT	1000.00	CARE PP-MLD AA; Stable	1)CARE PP-MLD AA (CWD) (06-Apr-22)	1)CARE PP-MLD AA (CWD) (11-Oct-21)	-	-
15	Debentures-Market Linked Debentures	LT	1000.00	CARE PP-MLD AA; Stable				

* Long Term / Short Term

Annexure-3: Detailed explanation of covenants of the rated instrument – Not Available

Name of the Instrument	Detailed explanation
A. Financial covenants	
I	
B. Non financial covenants	
I	

Annexure 4: Complexity level of various instruments rated for this company

Sr. No	Name of instrument	Complexity level
1	Commercial Paper (Standalone)	Simple
2	Inter Corporate Deposit	Simple
3	Short-Term Non-Convertible Debentures	Simple
4	Fund-based - LT-Term Loan	Simple
5	Fund-based - ST-Working Capital Limits	Simple
6	Non-Convertible Debentures	Simple
7.	Market Linked Debentures	Highly Complex

Annexure-5: Bank lender details for this company

To view the lender wise details of bank facilities please click here

Annexure 6: Entities considered for consolidation as on March 31, 2022

Sr. no.	Subsidiary	Extent of Consolidation (%)	Rationale for consolidation
1	PHL Fininvest Private Limited	100	Wholly-owned subsidiary
2	Piramal Capital & Housing Finance Limited	100	Wholly-owned subsidiary

Note on complexity levels of the rated instrument: CARE Ratings Ltd. has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Contact us

Media Contact
Name: Mradul Mishra
Phone: +91-22-6754 3573
E-mail: mradul.mishra@careedge.in

Analyst Contact
Name: Aditya R Acharekar
Phone: 9819013971
E-mail: aditya.acharekar@careedge.in

Relationship Contact
Name: Saikat Roy
Phone: +91-98209 98779
E-mail: saikat.roy@careedge.in

About us:
Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

For the detailed Rationale Report and subscription information, please visit www.careedge.in